Adenovirus-derived vectors for prostate cancer gene therapy

de Vrij, J.; Willemsen, R. A.; Lindholm, L.; Hoeben, R. C.; Bangma, Ch. H.; Barber, Ch.; Behr, J.-P.; Briggs, S.; Carlisle, R.; Cheng, W.-S.; Dautzenberg, I. J. C.; de Ridder, C.; Dzojic, H.; Erbacher, P.; Essand, M.; Fisher, K.; Frazier, A.; Georgopoulos, L. J.; Jennings, I.; Kochanek, S.; Koppers-Lalic, D.; Kraaij, R.; Kreppel, F.; Magnusson, M.; Maitland, N.; Neuberg, P.; Nugent, R.; Ogris, M.; Remy, J.-S.; Scaife, M.; Schenk, E.; Schooten, E.; Seymour, L.; Slade, M.; Szyjanowicz, P.; Totterman, T.; Uil, T. G.; Ulbrich, Karel; van der Weel, L.; van Weerden, W.; Wagner, E.; Zuber, G.

doi:https://dx.doi.org/10.1089/hum.2009.203

Number of the records: 1

Adenovirus-derived vectors for prostate cancer gene therapy

1.

SYSNO ASEP	0351866
Document Type	J - Journal Article
R&D Document Type	The record was not marked in the RIV
Subsidiary J	Článek ve WOS
Title	Adenovirus-derived vectors for prostate cancer gene therapy
Author(s)	de Vrij, J. (NL) Willemsen, R. A. (NL) Lindholm, L. (SE) Hoeben, R. C. (NL) Bangma, Ch. H. (NL) Barber, Ch. (NL) Behr, J.-P. (FR) Briggs, S. (SE) Carlisle, R. (GB) Cheng, W.-S. (SE) Dautzenberg, I. J. C. (NL) de Ridder, C. (NL) Dzojic, H. (SE) Erbacher, P. (FR) Essand, M. (SE) Fisher, K. (GB) Frazier, A. (GB) Georgopoulos, L. J. (GB) Jennings, I. (GB) Kochanek, S. (DE) Koppers-Lalic, D. (NL) Kraaij, R. (NL) Kreppel, F. (DE) Magnusson, M. (SE) Maitland, N. (GB) Neuberg, P. (GB) Nugent, R. (GB) Ogris, M. (DE) Remy, J.-S. (FR) Scaife, M. (GB) Schenk, E. (NL) Schooten, E. (NL) Seymour, L. (GB) Slade, M. (GB) Szyjanowicz, P. (GB) Totterman, T. (SE) Uil, T. G. (NL) Ulbrich, Karel (UMCH-V)_RID van der Weel, L. (NL) van Weerden, W. (NL) Wagner, E. (DE) Zuber, G. (FR)
Source Title	Human Gene Therapy. - : Mary Ann Liebert - ISSN 1043-0342 Roč. 21, č. 7 (2010), s. 795-805
Number of pages	11 s.
Language	eng - English
Country	US - United States
Keywords	adenovirus ; gene delivery ; prostate cancer
Subject RIV	CD - Macromolecular Chemistry
UT WOS	000279596700002
DOI	10.1089/hum.2009.203
Annotation	Prostate cancer is a leading cause of death among men in Western countries. Whereas the survival rate approaches 100% for patients with localized cancer, the results of treatment in patients with metastasized prostate cancer at diagnosis are much less successful. The patients are usually presented with a variety of treatment options, but therapeutic interventions in prostate cancer are associated with frequent adverse side effects. Gene therapy and oncolytic virus therapy may constitute new strategies. Already a wide variety of preclinical studies has demonstrated the therapeutic potential of such approaches, with oncolytic prostate-specific adenoviruses as the most prominent vector. The state of the art and future prospects of gene therapy in prostate cancer are reviewed, with a focus on adenoviral vectors. We summarize advances in adenovirus technology for prostate cancer treatment and highlight areas where further developments are necessary.
Workplace	Institute of Macromolecular Chemistry
Contact	Eva Čechová, cechova@imc.cas.cz ; Tel.: 296 809 358
Year of Publishing	2011

Number of the records: 1